BioSpace News Archive

Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain ‘non-hydroxamate’ inhibitors of LpxC for the treatment of Gram-negative bacterial infections.

Physicians Endoscopy (PE) today announced that the Company’s Board of Directors has appointed David Young as Chief Executive Officer. Young joined the Company in June 2018 as President. Barry Tanner, PE’s co-founder, has been named Chairman as part of his succession plan

Accellix Inc. announces the appointment of a new Board Member, Mr. Charles Piazza.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, and provided an overview of Atreca’s recent developments.

The Company looks forward to providing investors with updates on such expansion activities.

Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel.

Philanthropy honors life and contributions of co-founder Lori Newcomb

The space has been thoroughly redesigned.

The Pilot Program uses the StrainSecure™ technology as a master registry for standardized testing, product verification, and quality assurance.

AgeX Therapeutics, Inc., a biotechnology company focused on the development of therapeutics for human aging, reported financial and operating results for the second quarter ended June 30, 2019.